NCT02241759View on ClinicalTrials.gov

Study of the Electrocardiographic Effects of TA-8995

PHASE1CompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

December 31, 2014

Conditions
Dyslipidaemia
Interventions
DRUG

TA-8995

DRUG

Moxifloxacin

DRUG

Placebo

Trial Locations (1)

LS2 9LH

Covance Clinical Research Unit Ltd, Leeds

All Listed Sponsors
lead

Xention Ltd

INDUSTRY

NCT02241759 - Study of the Electrocardiographic Effects of TA-8995 | Biotech Hunter | Biotech Hunter